ChiCTR-DOD-16009648进行中（未招募）不适用
基于国际标准的攀高自动血压计准确性测试
深圳攀高电子有限公司1 个研究点 分布在 1 个国家开始时间: 2016年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 试验地点
- 1
- 主要终点
- 血压
研究概览
简要总结
依据欧洲高血压协会国际评估方案、英国高血压协会评估方案、AAMI/ISO 方案（EN 1060）等标准评价攀高全自动电子血压计准确性
研究设计
- 研究类型
- 诊断试验
- 主要目的
- 诊断试验诊断准确性
- 盲法
- 两位观察者之间相互设盲，并对设备测量值设盲。
入排标准
- 年龄范围
- 18 至 90（—）
- 性别
- All
入选标准
- •性别：男女基本均衡； 年龄范围：25 岁以上（ESH）或者成年人 / 儿童（按照标准纳入）； 心律：窦性心律； 血压范围：根据研究方案确定的收缩压与舒张压范围纳入的受试者符合方案要求。
排除标准
- •血压范围纳入完毕；范围调整；心律失常（不齐）；设备故障；听诊声音质量差；无合适袖带；观测值分歧；血压分布；与其它需要排除的情况。
结局指标
主要结局
血压
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention. - The SEPIA-PCI TrialPatients with coronary heart disease who will be undergoing non-urgent Percutaneous Coronary Intervention (PCI)EUCTR2004-000904-41-SKAventis Pharmaceuticals Inc.930
进行中（未招募）
1 期
A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention. - The SEPIA-PCI TrialPatients with coronary heart disease who will be undergoing non-urgent Percutaneous Coronary Intervention (PCI)EUCTR2004-000904-41-ESAventis Pharmaceuticals Inc.930
进行中（未招募）
不适用
A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention. - The SEPIA-PCI TrialPatients with coronary heart disease who will be undergoing non-urgent Percutaneous Coronary Intervention (PCI)EUCTR2004-000904-41-CZAventis Pharmaceuticals Inc.930
已完成
不适用
INTERNATIONAL MULTICENTRIC TEST FOR THE EVALUATION OF A COMBINED TABLET OF FOUR DRUGS AT DAILY FIXED DOSE IN THE INTENSIVE INITIAL PHASE (2 MONTHS) OF CHEMOTHERAPY FOLLOWED BY A COMBINED TABLET OF TWO DRUGS AT A FIXED DOSE THREE TIMES A WEEK IN THE CONTINUATION PHASE (4 MONTHS) FOR THE TREATMENT OF PULMONARY TUBERCULOSISPER-093-03nion Internacional contra TBC y enfermedades pulmonares,
进行中（未招募）
1 期
A clinical study in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy conducted to assess safety, tolerability and efficacy of LomitapideHomozygous familial hypercholesterolemia (HoFH).MedDRA version: 18.1Level: LLTClassification code 10057080Term: Homozygous familial hypercholesterolemiaSystem Organ Class: 100000004850EUCTR2014-003806-33-GRAegerion Pharmaceuticals Inc.45